Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above 200-Day Moving Average – Should You Sell?

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.67 and traded as high as $0.8142. Xtant Medical shares last traded at $0.7250, with a volume of 230,125 shares changing hands.

Analysts Set New Price Targets

Separately, BTIG Research dropped their price target on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $1.50.

Xtant Medical Stock Up 4.3%

The firm has a market capitalization of $101.50 million, a PE ratio of 72.57 and a beta of -0.05. The stock has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $0.67. The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its earnings results on Monday, November 10th. The medical device company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Institutional Investors Weigh In On Xtant Medical

Several institutional investors have recently made changes to their positions in XTNT. Jane Street Group LLC bought a new stake in shares of Xtant Medical during the 2nd quarter valued at $26,000. Mink Brook Asset Management LLC grew its holdings in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Crescent Grove Advisors LLC increased its position in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after buying an additional 200,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Xtant Medical in the second quarter valued at approximately $4,875,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.